Becker's Healthcare May 24, 2024
In a yearslong trial of more than 3,500 participants, Novo Nordisk’s Ozempic and Wegovy slowed the growth of chronic kidney disease and slashed the risk of heart attack, kidney failure, stroke and death.
The Novo Nordisk-run study tested how the drugs’ generic, semaglutide, or a placebo affected major kidney disease events, including kidney failure. In patients with diabetes and chronic kidney disease, semaglutide cut the risk of kidney disease-related events by 24%, the risk of a major heart problem by 18% and the risk of death by 20%, according to findings published May 24 in NEJM.
Fewer serious adverse events were reported in the semaglutide group (49.6%) than the placebo cohort (53.8%), too.
The study is the...
Today's Sponsors
Today's Sponsor